

Supplementary Table 4: Eight-week disease control rates by *EGFR* mutation status stratified by ECOG performance status (4a) and by the number of prior lines of therapy before inclusion in the trial (4b)

Table 4a:

ECOG	<i>EGFR</i> mutation	<i>EGFR</i> wild type
0	0% (0/2)	100% (2/2)
1	22% (2/9)	68% (39/57)
2	50% (1/2)	25% (2/8)
Total	23% (3/13)	64% (43/67)

Table 4b:

Prior treatments	<i>EGFR</i> mutation	<i>EGFR</i> wild type
0-1	0% (0/2)	43% (6/14)
>=2	27% (3/11)	70% (37/53)
Total	23% (3/13)	64% (43/67)